glbO Antibody

What is Globo H and why is it significant in cancer research?

Globo H is a hexasaccharide (a carbohydrate composed of six sugar units) that serves as a tumor-associated carbohydrate antigen. Its significance stems from its differential expression pattern: it is expressed at low levels in normal tissues but is highly expressed in multiple cancer types, including breast, gastric, pancreatic, and lung cancers . This unique expression profile makes Globo H an attractive target for cancer immunotherapy approaches.

Research indicates that Globo H shed by cancer cells appears to support carcinogenesis through multiple mechanisms: protection from apoptosis, suppression of immune cell activity, and promotion of angiogenesis . Additionally, Globo H has been observed in cancer stem cells, suggesting its potential role as a drug target for tumor eradication . The presence of Globo H across at least 15 different cancer types highlights its broad potential as a therapeutic target in oncology .

How does Globo H expression differ between normal tissues and cancer cells?

In normal tissues, Globo H is weakly expressed and primarily localized to apical epithelial cells at lumen borders, where access of the immune system is restricted . This limited expression and anatomical sequestration help prevent autoimmune responses against the antigen.

In contrast, cancer cells exhibit significantly higher expression levels of Globo H on their cell surface. This has been documented across multiple cancer types through flow cytometric analysis, including in breast, esophageal, colon, and oral cancers . Additionally, Globo H expression has been observed in gastric, pancreatic, and lung cancers . The differential expression creates a therapeutic window that can be exploited for targeted therapies.

The presence of Globo H in cancer stem cells is particularly significant as these cells are often implicated in therapy resistance, tumor recurrence, and metastasis . This makes Globo H a potential target not only for treating bulk tumor cells but also for eliminating the tumor-initiating cell population.

What methods are used to synthesize Globo H for research applications?

The synthesis of Globo H has evolved significantly over time, with several methodological approaches developed to enhance efficiency and scalability:

• Glycal Chemistry: The first synthesis of Globo H utilized glycal chemistry, which provided sufficient material for initial evaluation in phase I human trials .

• Programmable One-Pot Synthesis: This method represented a significant advancement, rendering the synthesis more practical and enabling phase II and III clinical trials. The approach involves a [1 + 2 + 3] strategy where the entire hexasaccharide is constructed in a single one-pot reaction .

• Enzymatic Synthesis: For late-stage multicenter trials and manufacturing, enzymatic synthesis coupled with cofactor regeneration was developed, offering improved scalability and potentially reduced costs .

Synthetic strategies typically incorporate linkers at the reducing end of the molecule for conjugation to carrier proteins or other molecules for vaccine or diagnostic applications. Examples include 1-aminopentyl or 1-azidopentyl linkers for immobilization on NHS-coated glass slides for microarray analysis .

How do antibody-drug conjugates targeting Globo H function mechanistically?

OBI-999 represents a state-of-the-art approach as a Globo H-targeting antibody-drug conjugate (ADC). Its mechanism of action involves multiple steps:

• Targeting and Binding: OBI-999 is derived from a conjugation of a Globo H-specific monoclonal antibody with a monomethyl auristatin E (MMAE) payload through a site-specific ThioBridge and a cleavable linker .

• Internalization and Trafficking: Upon binding to Globo H on the cancer cell surface, OBI-999 undergoes cellular internalization and traffics to the endosome within 1 hour and lysosome within 5 hours .

• Payload Release: In the lysosomal compartment, the Val-Cit-PAB linker is cleaved by cathepsin B, releasing the antimitotic MMAE payload .

• Cytotoxic Effect: The released MMAE disrupts microtubule function, leading to cell cycle arrest and apoptosis .

• Bystander Effect: OBI-999 has demonstrated a bystander killing effect on tumor cells with minimal Globo H expression, suggesting that released MMAE can affect neighboring cells regardless of their Globo H expression levels .

The ADC demonstrates high homogeneity with a drug-to-antibody ratio of 4 (>95%) achieved using ThioBridge technology . This consistent ratio is important for predictable pharmacokinetics and reduced batch-to-batch variability.

What is the evidence for efficacy of Globo H-targeting antibodies in preclinical models?

Preclinical studies of Globo H-targeting antibodies have demonstrated promising efficacy across multiple experimental models:

• OBI-999 (Antibody-Drug Conjugate):

  • Displayed low nanomolar cytotoxicity in tumor cells with high Globo H expression

  • Demonstrated excellent tumor growth inhibition in breast, gastric, and pancreatic cancer xenograft models in a dose-dependent manner

  • Showed efficacy in lung patient-derived xenograft (PDX) models

  • Tissue distribution studies revealed that OBI-999 and free MMAE gradually accumulated in tumors, reaching maximum levels at 168 hours after treatment, while decreasing quickly in normal organs

  • Maximum MMAE levels in tumors were 16-fold higher than in serum, suggesting selective delivery to target tissues

• OBI-888 (Humanized Monoclonal Antibody):

  • As a humanized IgG1 antibody specific to Globo H, OBI-888 has been evaluated in phase I-II clinical studies in patients with advanced cancer

  • The dosing regimen involved OBI-888 at 5, 10, or 20 mg/kg IV weekly in Part A ("3 + 3" design) and 20 mg/kg IV weekly in Part B (Simon's 2-stage design)

The preclinical efficacy data supported the advancement of both OBI-999 and OBI-888 into clinical trials, with OBI-999 currently in a phase I/II clinical study in multiple solid tumors (NCT04084366) .

How are carbohydrate microarrays used to characterize Globo H antibody interactions?

Carbohydrate microarrays have emerged as a powerful tool for profiling antibody interactions with Globo H and related structures. The methodology involves:

• Array Preparation: Synthetic Globo H and structural analogs (compounds 1-6) are immobilized on NHS-coated glass slides .

• Concentration Gradients: Compounds are spotted in concentration ranges (e.g., 1-100 μM) to enable antibody binding curve generation .

• Antibody Incubation: Slides are incubated with anti-Globo H monoclonal antibodies such as MBr1 (IgM) or VK-9 (IgG) .

• Detection: Binding is visualized using fluorescein-tagged secondary antibodies (e.g., goat anti-mouse IgM or IgG) .

• Analysis: Fluorescence scanning provides images where antibody binding to printed oligosaccharide spots can be directly observed and quantified .

This microarray method offers several advantages:

• Requires only picomole amounts of synthetic carbohydrates

• Allows simultaneous testing of multiple structures and antibodies

• Enables structure-activity relationship studies through systematic structural modifications

Studies using this approach have revealed that shorter oligosaccharides (truncated versions of Globo H) show weaker recruitment of antibodies to the plate surface . Additionally, the microarray platform has been used to test cancer patient serum for the presence of antibodies against Globo H analogs .

What pharmacokinetic considerations are important for Globo H-targeting therapies?

Pharmacokinetic studies of Globo H-targeting therapies reveal important considerations for clinical application:

• Tissue Distribution and Accumulation:

  • OBI-999 and free MMAE gradually accumulated in tumor tissue, reaching maximum levels at 168 hours after treatment

  • In contrast, levels in normal organs decreased quickly within 4 hours after treatment

  • The maximum MMAE level in tumors was 16-fold higher than in serum, suggesting selective accumulation at target sites

• Stability in Circulation:

  • Studies indicate that OBI-999 remains stable during circulation, with MMAE selectively released in the tumor environment

  • This stability is critical for minimizing systemic toxicity while maximizing drug delivery to the tumor

• Dosing Strategies:

  • For OBI-888, clinical trials have employed dosing regimens of 5, 10, or 20 mg/kg IV weekly

  • Treatment cycles are typically defined as 28 days in clinical protocols

• Maximum Tolerated Dose:

  • The highest non-severely toxic dose of OBI-999 in cynomolgus monkeys was determined to be 10 mg/kg in a 3-week repeated-dose toxicology study

  • This established an acceptable safety margin for initial human dosing

Understanding these pharmacokinetic profiles is essential for designing optimal treatment regimens, predicting drug exposure at tumor sites, and managing potential toxicities in clinical settings.

What strategies are employed to optimize immune responses to Globo H-based vaccines?

Developing effective Globo H-based vaccines faces the challenge of generating robust immune responses against carbohydrate antigens. Several strategies have been employed to address this challenge:

• Novel Adjuvant Design:

  • Development of new glycolipid adjuvants that target the CD1d receptor on dendritic cells and B cells for enhanced presentation to T cells

  • These specialized adjuvants help modulate the immune response and induce a class switch from IgM to IgG antibodies

• Carrier Protein Selection:

  • Conjugation of Globo H to immunogenic carrier proteins provides T cell epitopes necessary for robust B cell activation

  • The chemical approach to synthesis and conjugation offers flexibility for testing various structures and linkers to identify optimal compositions

• Broadening Epitope Recognition:

  • Research has discovered that Globo H vaccines can induce antibodies that target not only Globo H but also related structures like SSEA3 and SSEA4

  • This broader recognition profile potentially increases the efficacy against heterogeneous tumor populations

• Optimization of Synthetic Chemistry:

  • The development of programmable one-pot synthesis methods and enzymatic approaches has enabled practical synthesis of vaccine candidates for clinical development and commercialization

  • These methods allow for the production of consistent and well-characterized immunogens

The development path for Globo H vaccines illustrates the integration of chemistry with immunology and cancer biology to design effective cancer vaccines targeting specific glycan markers expressed on cancer cell surfaces .

What are the protocols for assessing Globo H expression in clinical samples?

Effective assessment of Globo H expression in clinical samples requires standardized protocols:

For immunohistochemistry protocols specifically, key steps include:

• Treatment with 0.05% Tween 20/PBS buffer (pH 7.4) for blocking

• Incubation with 50 μg/ml solution of MBr1 anti-Globo H monoclonal antibody (IgM) or VK-9 anti-Globo H monoclonal antibody (IgG)

• Application of coverslip and incubation in a glass humidifying chamber with shaking for 1 hour

• Washing three times with 0.05% Tween 20/PBS buffer (pH 7.4), three times with PBS buffer (pH 7.4), and three times with water

These standardized methods enable consistent assessment of Globo H expression across different laboratories and clinical settings.

How can researchers differentiate between different patterns of Globo H glycosylation in tumors?

Distinguishing various patterns of Globo H glycosylation in tumors requires specialized analytical approaches:

• Carbohydrate Microarray Analysis:

  • Arrays containing Globo H analogs with sequentially clipped sugars (compounds 1-4) and variations without the terminal fucose moiety (compounds 5-6) enable detailed epitope mapping

  • This approach allows researchers to determine which structural components of Globo H are essential for antibody recognition

• Fluorescence-Tagged Analytical Sequencing:

  • This method requires only picomole amounts of material and complements traditional methods for determining the structure of synthetic sugars

  • The combination of microarray and sequencing tools allows for thorough characterization of synthetic Globo H and its interactions with monoclonal antibody binding partners

• Mass Spectrometry-Based Glycomics:

  • Enables detailed structural characterization of glycans from tumor samples

  • Can identify subtle modifications in Globo H structure that may affect antibody recognition or biological function

• Comparative Binding Studies:

  • Testing antibody binding to Globo H versus related structures like SSEA3 and SSEA4 helps map epitope specificity

  • Binding curves generated across concentration ranges (1-100 μM) provide quantitative data on affinity differences

Understanding these glycosylation patterns is crucial for antibody development, as changes in Globo H structure can significantly impact antibody recognition and therapeutic efficacy.

What clinical trial designs are most appropriate for Globo H-targeting therapies?

Clinical trial designs for Globo H-targeting therapies must address the unique aspects of these agents:

• Phase I Dose-Finding Studies:

  • "3+3" design for initial dose escalation, as implemented with OBI-888 (5, 10, or 20 mg/kg IV weekly)

  • Primary endpoints typically include safety, tolerability, and determination of maximum tolerated dose (MTD)

  • Pharmacokinetic and preliminary efficacy assessments as secondary endpoints

• Phase II Efficacy Studies:

  • Simon's 2-stage design (as used in OBI-888 trials) to efficiently identify signals of efficacy while minimizing patient exposure to ineffective treatments

  • Single-arm studies may be appropriate for heavily pretreated populations with limited therapeutic options

  • Endpoints may include objective response rate, disease control rate (with stable disease ≥4 months considered clinical benefit)

• Basket Trial Approach:

  • Given Globo H expression across multiple tumor types, basket trials enrolling patients based on biomarker (Globo H) expression rather than tumor type may be appropriate

  • This design allows efficient evaluation across multiple indications simultaneously

• Combination Strategies:

  • Trials evaluating Globo H-targeting agents in combination with standard therapies or other novel agents

  • Adaptive designs that allow modification based on emerging data may be particularly valuable

For example, the phase I/II study of OBI-999 in multiple solid tumors (NCT04084366) and the phase I-II study of OBI-888 represent current approaches to clinical evaluation of these agents .

How does the tumor microenvironment influence efficacy of Globo H-targeting antibodies?

The tumor microenvironment plays a crucial role in determining the efficacy of Globo H-targeting therapies:

• Accessibility Factors:

  • Vascular density and permeability affect antibody penetration into solid tumors

  • Stromal barriers may limit distribution of antibodies or ADCs within tumors

  • The large molecular size of antibodies (approximately 150 kDa) presents physical limitations to tissue penetration

• Immune Cell Infiltration:

  • For antibodies relying on immune effector functions (ADCC, ADCP), the presence and activity of effector cells (NK cells, macrophages) in the tumor microenvironment is critical

  • Immunosuppressive conditions may reduce efficacy of immune-mediated mechanisms

• Lysosomal Function:

  • For ADCs like OBI-999, effective trafficking to lysosomes and activity of cathepsin B enzyme is essential for payload release

  • Alterations in endosomal-lysosomal pathways in cancer cells may affect ADC processing

• Heterogeneity of Globo H Expression:

  • Variability in Globo H expression within tumors may affect therapeutic response

  • The bystander killing effect observed with OBI-999 potentially addresses this challenge by affecting neighboring cells with minimal Globo H expression

• Hypoxia and pH:

  • Hypoxic regions and acidic pH in tumors may alter antibody stability, binding characteristics, or ADC processing

  • These microenvironmental conditions are common in solid tumors and may influence therapeutic efficacy

Understanding these interactions between Globo H-targeting therapies and the tumor microenvironment can guide patient selection strategies and combination approaches to enhance efficacy.

What combination strategies show promise for enhancing efficacy of Globo H-targeting therapies?

Several combinatorial approaches warrant investigation to potentially enhance the efficacy of Globo H-targeting therapies:

• Combination with Immune Checkpoint Inhibitors:

  • Pairing Globo H-targeting antibodies or ADCs with PD-1/PD-L1 inhibitors may enhance immune-mediated tumor killing

  • This approach could be particularly effective for antibodies that engage immune effector functions

• Synergy with Conventional Cytotoxics:

  • Sequential or concurrent administration with chemotherapeutics that have non-overlapping mechanisms of action with MMAE (for OBI-999)

  • Potential for chemotherapy to increase tumor permeability, enhancing antibody penetration

• Dual-Targeting Approaches:

  • Combining Globo H-targeting with agents targeting other tumor-associated antigens to address tumor heterogeneity

  • This strategy may minimize the emergence of resistance through antigen loss or downregulation

• Targeting Cancer Stem Cell Pathways:

  • Given Globo H expression on cancer stem cells, combination with agents targeting stemness pathways (Notch, Wnt, Hedgehog) could enhance elimination of tumor-initiating cells

  • This may improve long-term outcomes by preventing recurrence

• Radiation Therapy Combinations:

  • Radiation may upregulate tumor antigens and increase vascular permeability, potentially enhancing the efficacy of subsequent antibody therapy

  • Radiation also induces immunogenic cell death, which could synergize with immune-activating properties of antibodies

Preclinical evaluation of these combination strategies, followed by carefully designed clinical trials, will be essential to determine the most effective approaches for maximizing the therapeutic potential of Globo H-targeting therapies.

What are the challenges in developing next-generation Globo H-targeting therapeutics?

Development of next-generation Globo H-targeting therapeutics faces several key challenges:

• Optimizing Drug-to-Antibody Ratio and Linker Chemistry:

  • While OBI-999 achieved high homogeneity with a drug-to-antibody ratio of 4 (>95%) using ThioBridge technology , further refinements may enhance stability or efficacy

  • Novel linker chemistries that optimize stability in circulation while ensuring efficient payload release in tumors are needed

• Expanding Payload Options:

  • Current ADCs like OBI-999 utilize MMAE as the cytotoxic payload

  • Exploring alternative payloads with different mechanisms of action could expand efficacy across diverse tumor types or overcome resistance mechanisms

• Addressing Heterogeneity of Expression:

  • Despite the bystander effect of OBI-999 , heterogeneous Globo H expression remains a challenge

  • Developing strategies to upregulate Globo H expression or targeting multiple antigens simultaneously may be beneficial

• Enhancing Tumor Penetration:

  • The large size of antibodies limits tumor penetration, particularly in solid tumors with dense stroma

  • Smaller formats like antibody fragments or alternative scaffolds may improve tissue distribution

• Managing Immunogenicity:

  • Despite humanization, anti-drug antibodies may develop against therapeutic antibodies

  • Strategies to mitigate immunogenicity while maintaining efficacy are needed

• Biomarker Development:

  • Improved methods for quantifying Globo H expression in tumors and monitoring therapeutic response

  • Identification of additional biomarkers that predict response to Globo H-targeting therapies

Addressing these challenges will require interdisciplinary approaches combining advances in antibody engineering, synthetic chemistry, glycobiology, and clinical trial design to develop more effective Globo H-targeting therapies for cancer treatment.